A Unifying Hypothesis for Scleroderma: Identifying a Target Cell for Scleroderma

被引:16
|
作者
Mahoney, William M., Jr. [1 ]
Fleming, Jo Nadine [1 ]
Schwartz, Stephen M. [1 ]
机构
[1] Univ Washington, Sch Med, Ctr Cardiovasc Biol, Dept Pathol, Seattle, WA 98109 USA
关键词
Type; 1; interferon; Vasculopathy; Fibrosis; Adventitial stem cell; RGS5; SYSTEMIC-SCLEROSIS; INTERFERON-ALPHA; STRUCTURAL-CHANGES; PERICYTE COVERAGE; FIBROTIC DISEASES; MESSENGER-RNA; PDGF-B; RGS5; EXPRESSION; THERAPY;
D O I
10.1007/s11926-010-0152-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We propose that a recent change in the conception of the role of type 1 interferon and the identification of adventitial stem cells suggests a unifying hypothesis for scleroderma. This hypothesis begins with vasospasm. Vasospasm is fully reversible unless, as proposed here, the resulting ischemia leads to apoptosis and activation of type 1 interferon. The interferon, we propose, initiates immune amplification, including characteristic scleroderma-specific antibodies. We propose that the interferon also acts on adventitial stem cells, producing myofibroblasts, rarefaction, and intimal hyperplasia-three morphologic changes that characterize this disease. Regulator of G-protein signaling 5 (RGS5), a regulator of vasoactive G-protein-coupled receptors, is a cell type-specific marker of pericytes and scleroderma myofibroblasts. RGS5 may provide a key link between initial hyperplasia and fibrosis in this disease.
引用
收藏
页码:28 / 36
页数:9
相关论文
共 50 条
  • [1] A Unifying Hypothesis for Scleroderma: Identifying a Target Cell for Scleroderma
    William M. Mahoney
    Jo Nadine Fleming
    Stephen M. Schwartz
    Current Rheumatology Reports, 2011, 13 : 28 - 36
  • [2] THE AUTOANTIGEN IN SCLERODERMA HYPOTHESIS
    ASHAMALLA, L
    SAUDI MEDICAL JOURNAL, 1990, 11 (03) : 253 - 254
  • [3] DRUG ON TARGET FOR SCLERODERMA CRISIS
    不详
    EMERGENCY MEDICINE, 1979, 11 (11) : 82 - &
  • [4] Scleroderma with Nodular Scleroderma
    Srisuttiyakorn, Chutika
    Aunhachoke, Kobkul
    CASE REPORTS IN DERMATOLOGY, 2016, 8 (03): : 303 - 310
  • [5] MICRO-VASCULAR PATHOGENESIS OF SCLERODERMA - HYPOTHESIS
    FRIES, JF
    ANNALS OF INTERNAL MEDICINE, 1979, 91 (05) : 788 - 789
  • [6] When is scleroderma really scleroderma?
    Wigley, FM
    JOURNAL OF RHEUMATOLOGY, 2001, 28 (07) : 1471 - 1473
  • [7] NOT ALL SCLERODERMA IS THE SAME SCLERODERMA
    Fleming, John S.
    Di Felice, Christopher
    Schauer, Mark
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2016, 31 : S687 - S688
  • [8] Stem cell therapy in scleroderma
    Braun-Moscovici, Y
    Furst, DE
    CURRENT OPINION IN RHEUMATOLOGY, 2002, 14 (06) : 711 - 716
  • [9] SCLERODERMA - SCLERODERMA RENAL DISEASE
    ROSENHEIM, M
    CASTLEMAN, B
    KRANES, A
    ROPES, MW
    CALKINS, E
    RICHARDSON, EP
    NEW ENGLAND JOURNAL OF MEDICINE, 1956, 254 (21): : 998 - 1002
  • [10] Pirin: A new target to prevent fibrosis in scleroderma?
    Pourzan, Genevieve
    Basa, Grace
    Lisabeth, Erika Mathes
    Neubig, Richard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB105 - AB105